Guanjun Chen

Changsha, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Research progress in augmentation strategies for PD-1/PD-L1 inhibitors in bladder cancer: from biological determinants to clinical applications.

Research progress in augmentation strategies for PD-1/PD-L1 inhibitors in bladder cancer: from biological determinants to clinical applications.

Journal: Frontiers in immunology

Published: February 02, 2026

Dissecting the role of SEPHS1 in shaping an immunosuppressive microenvironment to promote tumor progression.

Dissecting the role of SEPHS1 in shaping an immunosuppressive microenvironment to promote tumor progression.

Journal: Cancer immunology, immunotherapy : CII

Published: August 28, 2025

TRMT6/TRMT61A-mediated tRNA m1A modification enhances protein translation and activates the IRE1α-XBP1s pathway to promote anaplastic thyroid cancer progression.

TRMT6/TRMT61A-mediated tRNA m1A modification enhances protein translation and activates the IRE1α-XBP1s pathway to promote anaplastic thyroid cancer progression.

Journal: Cellular & molecular biology letters

Published: July 21, 2025

SRSF10 promotes cisplatin resistance in bladder cancer via BIN1 Exon 12 retention and ANXA1 activation.

SRSF10 promotes cisplatin resistance in bladder cancer via BIN1 Exon 12 retention and ANXA1 activation.

Journal: Oncogene

Published: May 16, 2025

WGX50 attenuates radiation enteritis by targeting ferroptosis and redox homeostasis via EGFR.

WGX50 attenuates radiation enteritis by targeting ferroptosis and redox homeostasis via EGFR.

Journal: Molecular medicine (Cambridge, Mass.)

Published: March 20, 2025

Comprehensive Multi-Omics Analysis Identifies FUT1 as a Prognostic and Therapeutic Biomarker Across Pan-Cancer.

Comprehensive Multi-Omics Analysis Identifies FUT1 as a Prognostic and Therapeutic Biomarker Across Pan-Cancer.

Journal: International journal of medical sciences

Published: December 03, 2024

Development of an m6A subtype classifier to guide precision therapy for patients with bladder cancer.

Development of an m6A subtype classifier to guide precision therapy for patients with bladder cancer.

Journal: Journal of Cancer

Published: June 11, 2024

Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma.

Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma.

Journal: BMC cancer

Published: March 25, 2024

Identifying disulfidptosis subtypes in hepatocellular carcinoma through machine learning and preliminary exploration of its connection with immunotherapy.

Identifying disulfidptosis subtypes in hepatocellular carcinoma through machine learning and preliminary exploration of its connection with immunotherapy.

Journal: Cancer cell international

Published: December 26, 2023

WGX50 mitigates doxorubicin-induced cardiotoxicity through inhibition of mitochondrial ROS and ferroptosis.

WGX50 mitigates doxorubicin-induced cardiotoxicity through inhibition of mitochondrial ROS and ferroptosis.

Journal: Journal of translational medicine

Published: August 25, 2023

Construction of the novel immune risk scoring system related to CD8+ T cells in uterine corpus endometrial carcinoma.

Construction of the novel immune risk scoring system related to CD8+ T cells in uterine corpus endometrial carcinoma.

Journal: Cancer cell international

Published: February 14, 2023

Construction of a novel molecular typing and scoring system for anoikis distinguishes between different prognostic risks and treatment responsiveness in low-grade glioma.

Construction of a novel molecular typing and scoring system for anoikis distinguishes between different prognostic risks and treatment responsiveness in low-grade glioma.

Journal: Frontiers in immunology

Published: November 22, 2022

Showing 1-12 of 12

Last Updated: 09/26/2026